Имплантация окклюдера ушка левого предсердия для профилактики системных эмболий. Первый опыт в СевероЗападном регионе

Впервые представляются случаи успешной имплантации различных окклюдеров в ушко левого предсердия в Северо-Западном регионе РФ с целью профилактики системных тромбоэмболий. Имплантация окклюдеров достаточно безопасная и эффективная процедура, позволяющая отменить постоянный прием пероральных антикоагулянтов. Имплантация окклюдера может быть альтернативой при высоком риске кровотечений и ограничениях постоянной антикоагулянтной терапии.

фибрилляция предсердий, инсульт, ушко левого предсердия, антикоагулянты, имплантация окклюдера, atrial fibrillation, stroke, left atrial appendage, anticoagulants, occluder implantation

1. Go A.S., et al. Heart Disease and Stroke Statistics-2014 Update. Circulation. 2014; 128: 00-00

2. Watson T., Shantsila E., Lip G.Y. Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet. 2009; 373: 155-166.

3. Zateyschikov D.A., Zotova I.V., Dankovtseva E.N. et al. Thrombotic events and antithrombotic therapy for arrhythmias. M.: Practice, 2011. p. 264. In Russian [Затейщиков Д.А., Зотова И.В., Данковцева Е.Н., Сидоренко Б.А. Тромбозы и антитромботическая терапия при аритмиях. М.: Практика, 2011. c. 264]

4. Marini C., De Santis F., Sacco S., et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke. 2005; 36: 1115-1119.

5. Lip G.Y., Nieuwlaat R., Pisters R. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor based approach: the euro heart survey on atrial fibrillation. Chest. 2010; 137(2): 263-272.

6. Lip G.Y., Frison L., Halperin J.L. et all. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED score. J Am CollCardiol. 2011; 173-180.

7. Lip GY, Edwards SJ. Stroke prevention with aspirin, warfarin and ximelagatran in patients with nonvalvular atrial fibrillation: a systematic review and metaanalysis. ThrombRes. 2006;118: 321-333.

8. Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.Ann Intern Med. 2007; 146(12): 857-867.

9. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12): 1139-1151.

10. Patel M.R., Mahaffey K.W., Gard J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10): 883-891.

11. Granger C.B., Alexander J.H., McMurray J.J. et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11): 981-992.

12. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation. 1991; 84(2): 527-539.

13. Reddy V.Y., Holmes D., Doshi S.K., et al. Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry. Circulation. 2011; 123: 417-424.

14. Reddy V.Y., Doshi S.K., Sievert H., et al. PROTECT AF Investigators. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-year follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial. Circulation. 2013; 127(6): 720-729.

15. Holmes D.R.Jr., Kar S., Price M.J., et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J AmCollCardiol. 2014; 64(1): 1-12.

16. Meier B., Blaauw Y., Khattab A.A. et all. EHRA/ EAPCI expert consensus statement on catheter-based left atrial appendage occlusion. EuroIntervention. 2014; 10: 1109-1125.

17. Boersma L., Schmidt B., Betts T. et all. EWOLUTION: design of a registry to evaluate real-world clinical outcomes in patients with AF and high stroke risk-treated with the WATCHMAN left atrial appendage closure technology. Catheter Cardiovasc Interv. 2016; in press.

18. Holmes D.R. Jr., Kar S., Price M.J. et all. Prospective randomized evaluation of the WATCHMAN left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J AmCollCardiol. 2014; 64: 1-12.

19. Tzikas A., Shakir S., Gafoor S., Omran H., Berti S., Santoro G., Kefer J., Landmesser U., Nielsen-Kudsk J.E., Cruz-Gonzalez I., Sievert H., Tichelbäcker T., Kanagaratnam P., Nietlispach F., Aminian A., Kasch F., Freixa X., Danna P., Rezzaghi M., Vermeersch P., Stock F., Stolcova M., Costa M., Ibrahim R., Schillinger W., Meier B., Park J.W. Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug. EuroIntervention. 2016; 11(10): 1170-1179.

20. Mikhaylov E.N., Lebedev D.S., Gureev S.V. et al. Safety of combination of indirect and direct anticoagulants during catheter ablation of atrial fibrillation: a study on a large group of patients. Journal of arrhythmology. 2008; 53: 21-26. In Russian [Михайлов Е.Н., Лебедев Д.С., Гуреев С.В. и др. Безопасность одновременного применения непрямых и прямых антикоагулянтов при катетерной аблации фибрилляции предсердий: исследование на большой группе пациентов. Вестник аритмологии. 2008; 53: 21-26.]